Managing cardiovascular risk in patients with metabolic syndrome

Clinical Cornerstone

Volumn 8, Issue SUPPL. 1, 2006, Pages

  Bassand, Jean Pierre ^a  

^a UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; NICOTINIC ACID; PIOGLITAZONE; RIMONABANT; THIAZIDE DIURETIC AGENT;

AGING; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CLINICAL TRIAL; DIET RESTRICTION; DRUG MECHANISM; DRUG TARGETING; DYSLIPIDEMIA; GLYCEMIC CONTROL; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INFLAMMATION; LIFESTYLE; LIPID METABOLISM; METABOLIC SYNDROME X; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHYSICAL ACTIVITY; RHABDOMYOLYSIS; RISK ASSESSMENT; RISK MANAGEMENT; RISK REDUCTION; THROMBOSIS; TREATMENT PLANNING; WEIGHT REDUCTION;

ACTIVITIES OF DAILY LIVING; ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; METABOLIC SYNDROME X; RISK FACTORS; SMOKING CESSATION; TREATMENT OUTCOME;

EID: 33747834349     PISSN: 10983597     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1098-3597(06)80003-7     Document Type: Article

References (64)

1. Cameron A., Shaw J., and Zimmet P. The metabolic syndrome: Prevalence in worldwide populations. Endocrinol Metab Clin North Am 33 (2004) 351-375
2. DeFronzo R., and Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14 (1991) 173-194
3. Grundy S., Hansen B., Smith Jr. S., et al. Clinical management of metabolic syndrome: Report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association Conference on Scientific Issues Related to Management. Circulation 109 (2004) 551-556
4. Kaplan N. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 149 (1989) 1514-1520
5. Reaven G. Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes 37 (1988) 1595-1607
6. Alberti K., and Zimmet P. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet Med 15 (1998) 539-553
7. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
8. Reaven G. The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinol Metab Clin N Am 33 (2004) 283-303
9. Hanley A., Festa A., D'Agostino Jr. R., et al. Metabolic and inflammation variable clusters and prediction of type 2 diabetes: Factor analysis using directly measured insulin sensitivity. Diabetes 53 (2004) 1773-1781
10. Grundy S., Brewer Jr. H., Cleeman J., et al. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. Circulation 109 (2004) 433-438
11. Hanson R., Imperatore G., Bennett P., and Knowler W. Components of the "metabolic syndrome" and incidence of type 2 diabetes. Diabetes 51 (2002) 3120-3127
12. Laaksonen D., Lakka H., Niskanen L., et al. Metabolic syndrome and development of diabetes mellitus: Application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol 156 (2002) 1070-1077
13. Stern M., Williams K., Gonzalez-Villalpando C., et al. Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease?. Diabetes Care 27 (2004) 2676-2681
14. Bhargava A. A longitudinal analysis of the risk factors for diabetes and coronary heart disease in the Framingham Offspring Study. Popul Health Metr 1 (2003) 3
15. Lakka H., Laaksonen D., Lakka T., et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288 (2002) 2709-2716
16. Isomaa B., Almgren P., Tuomi T., et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24 (2001) 683-689
17. Girman C., Rhodes T., Mercuri M., et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 93 (2004) 136-141
18. Malik S., Wong N., Franklin S., et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 110 (2004) 1245-1250
19. Nesto R. Correlation between cardiovascular disease and diabetes mellitus: Current concepts. Am J Med 116 Suppl 5A (2004) 11S-22S
20. Eckel R., Grundy S., and Zimmet P. The metabolic syndrome. Lancet 365 (2005) 1415-1428
21. Grundy S., Cleeman J., Daniels S., et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112 (2005) 2735-2752
22. Assmann G., Cullen P., and Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the Prospective Cardiovascular Munster (PROCAM) study. Circulation 105 (2002) 310-315
23. Wilson P. Estimating cardiovascular disease risk and the metabolic syndrome: A Framingham view. Endocrinol Metab Clin North Am 33 (2004) 467-481
24. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation 106 (2002) 3143-3421
25. Conroy R., Pyorala K., Fitzgerald A., et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: The SCORE Project. Eur Heart J 24 (2003) 987-1003
26. De Backer G., Ambrosioni E., Borch-Johnsen K., et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 24 (2003) 1601-1610
27. National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. The Evidence Report. Obes Res. 6 Suppl 2 (1998) 51S-209S
28. Knowler W., Barrett-Connor E., Fowler S., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 346 (2002) 393-403
29. Ridker P., Cannon C., Morrow D., et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 352 (2005) 20-28
30. Pearson T., Mensah G., Alexander R., et al. Markers of inflammation and cardiovascular disease: Application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107 (2003) 499-511
31. Grundy S., Abate N., and Chandalia M. Diet composition and the metabolic syndrome: What is the optimal fat intake?. Am J Med. 113 Suppl 9B (2002) 25S-29S
32. de Lorgeril M., Renaud S., Mamelle N., et al. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet 343 (1994) 1454-1459
33. Singh R., Dubnov G., Niaz M., et al. Effect of an Indo-Mediterranean diet on progression of coronary artery disease in high risk patients (Indo-Mediterranean Diet Heart Study): A randomised single-blind trial. Lancet 360 (2002) 1455-1461
34. Thompson P., Buchner D., Pina I., et al. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: A statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity). Circulation 107 (2003) 3109-3116
35. for the Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. Tuomilehto J., Lindstrom J., Eriksson J., et al. N Engl J Med 344 (2001) 1343-1350
36. Franklin B., Kahn J., Gordon N., and Bonow R. A cardioprotective "polypill"? Independent and additive benefits of lifestyle modification. Am J Cardiol 94 (2004) 162-166
37. Ridker P., Cannon C., Morrow D., et al., PROVE-IT TIMI 22 Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352 (2005) 20-28
38. Collins R., Armitage J., Parish S., et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial. Lancet 361 (2003) 2005-2016
39. LaRosa J., Grundy S., Waters D., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 (2005) 1425-1435
40. Shepherd J., Cobbe S., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333 (1995) 1301-1307
41. Rubins H. Triglycerides and coronary heart disease: Implications of recent clinical trials. J Cardiovasc Risk 7 (2000) 339-345
42. Chang J., Staffa J., Parks M., and Green L. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy. Pharmacoepidemiol Drug Saf. 13 (2004) 417-426
43. Bergman A., Murphy G., Burke J., et al. Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans. J Clin Pharmacol 44 (2004) 1054-1062
44. Rubins H., Robins S., Collins D., et al. Diabetes, plasma insulin, and cardiovascular disease: Subgroup analysis from the Department of Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT). Arch Intern Med 162 (2002) 2597-2604
45. Canner P., Furberg C., Terrin M., and McGovern M. Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol 95 (2005) 254-257
46. Bays H., Dujovne C., McGovern M., et al. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-modulating Agents Trial Evaluation [ADVOCATE]). Am J Cardiol 91 (2003) 667-672
47. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: Results of prospectively designed overviews of randomised trials. Lancet 362 (2003) 1527-1535
48. Dahlof B., Devereux R., Kjeldsen S., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 359 (2002) 995-1003
49. Lindholm L., Ibsen H., Dahlof B., et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 359 (2002) 1004-1010
50. Dahlof B., Sever P., Poulter N., et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial. Lancet 366 (2005) 895-906
51. Poulter N., Wedel H., Dahlof B., et al. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 366 (2005) 907-913
52. Knowler W., Hamman R., Edelstein S., et al. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 54 (2005) 1150-1156
53. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
54. Dormandy J., Charbonnel B., Eckland D., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macro Vascular Events): A randomised controlled trial. Lancet 366 (2005) 1279-1289
55. Lindholm L., Carlberg B., and Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 366 (2005) 1545-1553
56. Carlberg B., Samuelsson O., and Lindholm L. Atenolol in hypertension: Is it a wise choice?. Lancet 364 (2004) 1684-1689
57. Lind L., Pollare T., Berne C., and Lithell H. Long-term metabolic effects of antihypertensive drugs. Am Heart J 128 (1994) 1177-1783
58. Neutel J. Metabolic manifestations of low-dose diuretics. Am J Med 101 (1996) 71S-82S
59. Grassi G., Seravalle G., Dell'Oro R., et al. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: Results of the CROSS study. J Hypertens 21 (2003) 1761-1769
60. Lindholm L., Persson M., Alaupovic P., et al. Metabolic outcome during 1 year in newly detected hypertensives: Results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens 21 (2003) 1563-1574
61. Womack C., Nagelkirk P., and Coughlin A. Exercise-induced changes in coagulation and fibrinolysis in healthy populations and patients with cardiovascular disease. Sports Med 33 (2003) 795-807
62. Nissen S., Tuzcu E., Schoenhagen P., et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 352 (2005) 29-38
63. Van Gaal L., Rissanen A., Scheen A., et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-Year experience from the RIO-Europe study. Lancet 365 (2005) 1389-1397
64. Despres J., Golay A., and Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353 (2005) 2121-2134